{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:25:15Z","timestamp":1793744715738,"version":"4.6.1"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a poor prognosis despite the advent of novel therapies. Consequently, a major need exists for new therapeutic options, particularly for patients with relapsed\/refractory (R\/R) AML. In recent years, it has been possible to individualize the treatment of a subgroup of patients, particularly with the emergence of multiple targeted therapies. Nonetheless, a considerable number of patients remain without therapeutic options, and overall prognosis remains poor because of a high rate of disease relapse. In this sense, cellular therapies, especially chimeric antigen receptor (CAR)-T cell therapy, have dramatically shifted the therapeutic options for other hematologic malignancies, such as diffuse large B cell lymphoma and acute lymphoblastic leukemia. In contrast, effectively treating AML with CAR-based immunotherapy poses major biological and clinical challenges, most of them derived from the unmet need to identify target antigens with expression restricted to the AML blast without compromising the viability of the normal hematopoietic stem cell counterpart. Although those limitations have hampered CAR-T cell therapy translation to the clinic, there are several clinical trials where target antigens, such as CD123, CLL-1 or CD33 are being used to treat AML patients showing promising results. Moreover, there are continuing efforts to enhance the specificity and efficacy of CAR-T cell therapy in AML. These endeavors encompass the exploration of novel avenues, including the development of dual CAR-T cells and next-generation CAR-T cells, as well as the utilization of gene editing tools to mitigate off-tumor toxicities. In this review, we will summarize the ongoing clinical studies and the early clinical results reported with CAR-T cells in AML, as well as highlight CAR-T cell limitations and the most recent approaches to overcome these barriers. We will also discuss how and when CAR-T cells should be used in the context of AML.<\/jats:p>","DOI":"10.3389\/fcell.2024.1376554","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T04:52:53Z","timestamp":1713329573000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations"],"prefix":"10.3389","volume":"12","author":[{"given":"Beatriz","family":"Guijarro-Albaladejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Marrero-Cepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Rodr\u00edguez-Arbol\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Sierro-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Garc\u00eda-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger","year":"2022","journal-title":"Blood Cancer J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1268","DOI":"10.1002\/CTI2.1268","article-title":"Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma","volume":"10","author":"Alvarez-Fern\u00e1ndez","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/J.YMTHE.2018.03.003","article-title":"Myeloid conditioning with c-kit-Targeted CAR-T cells enables donor stem cell engraftment","volume":"26","author":"Arai","year":"2018","journal-title":"Mol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"PR14","DOI":"10.1158\/2326-6074.TUMIMM18-PR14","article-title":"Abstract PR14: CD123CAR displays clinical activity in relapsed\/refractory (r\/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): safety and efficacy results from a phase 1 study","volume":"8","author":"Budde","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1270843","DOI":"10.3389\/FIMMU.2023.1270843","article-title":"Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia","volume":"14","author":"Calvi\u00f1o","year":"2023","journal-title":"Front. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/S13045-022-01376-3","article-title":"Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia","volume":"15","author":"Caruso","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1097\/HS9.0000000000000188","article-title":"CAR-T cells: future perspectives","volume":"3","author":"Charrot","year":"2019","journal-title":"Hemasphere"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/BLOOD-2021-148649","article-title":"Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies","volume":"138","author":"Choi","year":"2021","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/J.CLML.2021.10.013","article-title":"Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma","volume":"22","author":"Costa","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/S12943-022-01559-Z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: prognostic and therapeutic implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1182\/BLOOD.2021014670","article-title":"Single-cell genomics in AML: extending the frontiers of AML research","volume":"141","author":"Ediriwickrema","year":"2023","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/BLOOD-2022-168877","article-title":"Phase 1 dose escalation study of the rapidly switchable universal CAR-T therapy unicar-T-CD123 in relapsed\/refractory AML","volume":"140","author":"Ehninger","year":"2022","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/S41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"el Khawanky","year":"2021","journal-title":"Nat. Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/FONC.2020.00262","article-title":"A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/S41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood.2021015020","article-title":"Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies","volume":"140","author":"Freiwan","year":"2022","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1152498","DOI":"10.3389\/fimmu.2023.1152498","article-title":"Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies","volume":"14","author":"Garc\u00eda-Calder\u00f3n","year":"2023","journal-title":"Front. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3389\/FIMMU.2020.01128","article-title":"Overcoming chimeric antigen receptor (CAR) modified T-cell therapy limitations in multiple myeloma","volume":"11","author":"Garc\u00eda-Guerrero","year":"2020","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"650","DOI":"10.22074\/CELLJ.2021.7314","article-title":"Design and production an effective bispecific tandem chimeric antigen receptor on T cells against CD123 and folate receptor \u00df towards B-acute myeloid leukaemia blasts","volume":"23","author":"Ghamari","year":"2021","journal-title":"Cell J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","article-title":"CD7 CAR T cells for the therapy of acute myeloid leukemia","volume":"27","author":"Gomes-Silva","year":"2019","journal-title":"Mol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2174\/1389450116666150223120005","article-title":"Novel antigen targets for immunotherapy of acute myeloid leukemia","volume":"18","author":"Goswami","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"B29","doi-asserted-by":"publisher","first-page":"755639","DOI":"10.3389\/FIMMU.2021.755639","article-title":"Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-cell malignancies","volume":"12","author":"Guercio","year":"2021","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1182\/bloodadvances.2023010392","article-title":"Phase 1\/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML","volume":"7","author":"Halpern","year":"2023","journal-title":"Blood Adv."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.3390\/CELLS10123376","article-title":"The role of T cell immunotherapy in acute myeloid leukemia","volume":"10","author":"Hao","year":"2021","journal-title":"Cells"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/J.CCELL.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/BLOOD.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/S41467-022-28243-6","article-title":"CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells","volume":"13","author":"Hebbar","year":"2022","journal-title":"Nat. Commun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.4049\/JIMMUNOL.1200796","article-title":"Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKg2d-mediated NK cell responses","volume":"189","author":"Hilpert","year":"2012","journal-title":"J. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/S41422-022-00721-Y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1182\/BLOOD-2022-170712","article-title":"Off-the-Shelf CD33 CAR-NK cell therapy for relapse\/refractory AML: first-in-human, phase I trial","volume":"140","author":"Huang","year":"2022","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41375-018-0277-8","article-title":"Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR\/Cas9-deletion of CD33 exon 2","volume":"33","author":"Humbert","year":"2018","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3\u2212ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/S13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"100236","DOI":"10.1016\/J.CRMETH.2022.100236","article-title":"Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV","volume":"2","author":"Kararoudi","year":"2022","journal-title":"Cell Rep. Methods"},{"key":"B43","doi-asserted-by":"publisher","first-page":"707542","DOI":"10.3389\/FIMMU.2021.707542","article-title":"CAR-NK cells: from natural basis to design for kill","volume":"12","author":"Khawar","year":"2021","journal-title":"Front. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/J.CELL.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e120974","DOI":"10.1172\/JCI.INSIGHT.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"key":"B46","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/0006-291x(87)90502-x","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B47","first-page":"328","article-title":"Acute myeloid leukemia\u2014genetic alterations and their clinical prognosis","volume":"11","author":"Lagunas-Rangel","year":"2017","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"14331","DOI":"10.1073\/PNAS.1916206117","article-title":"Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia","volume":"117","author":"Lamble","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","article-title":"Effective killing of acute myeloid leukemia by TIM-3 targeted chimeric antigen receptor T cells","volume":"20","author":"Lee","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/J.CCELL.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/S12943-022-01541-9","article-title":"A novel approach for relapsed\/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv\/NKG2D-CAR T cells and gilteritinib","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3892\/MMR.2021.11847","article-title":"Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed\/refractory acute myeloid leukemia","volume":"23","author":"Lin","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/BLOOD-2018-99-110579","article-title":"First-in-Human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"B54","first-page":"S149","article-title":"First-in-human CLL1-CD33 compound CAR (cCAR) T cell therapy in relapsed and refractory acute myeloid leukemia","volume":"294969","author":"Liu","year":"2020","journal-title":"EHA Libr."},{"key":"B55","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/FIMMU.2019.00456","article-title":"Building potent chimeric antigen receptor T cells with CRISPR genome editing","volume":"10","author":"Liu","year":"2019","journal-title":"Front. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/IJC.33865","article-title":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"150","author":"Liu","year":"2022","journal-title":"Int. J. Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/J.OMTO.2020.04.009","article-title":"Rapidly switchable universal CAR-T cells for treatment of cd123-positive leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1182\/BLOOD-2014-11-612721","article-title":"Targeting of folate receptor \u03b2 on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/S13045-019-0726-5","article-title":"Targeting CLL-1 for acute myeloid leukemia therapy","volume":"12","author":"Ma","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B60","first-page":"615","article-title":"Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment","volume":"12","author":"Ma","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/S43018-023-00652-6","article-title":"Structural surfaceomics reveals an AML-specific conformation of integrin \u03b22 as a CAR T cellular therapy target","volume":"4","author":"Mandal","year":"2023","journal-title":"Nat. Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T cells for acute myeloid leukemia: state of the art and future directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/CANCERS14030497","article-title":"Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia","volume":"14","author":"Marvin-Peek","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"6157","DOI":"10.3390\/cancers13246157","article-title":"Current limitations and perspectives of chimeric antigen receptor-T-cells in acute myeloid leukemia","volume":"13","author":"Maucher","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B65","doi-asserted-by":"publisher","first-page":"780442","DOI":"10.3389\/FIMMU.2021.780442","article-title":"T cell fitness and autologous CAR T cell therapy in haematologic malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front. Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front. Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","first-page":"811144","DOI":"10.3389\/FIMMU.2022.811144","article-title":"Tumor microenvironment in acute myeloid leukemia: adjusting niches","volume":"13","author":"Menter","year":"2022","journal-title":"Front. Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.3390\/cancers13133214","article-title":"CD33 expression and gentuzumab ozogamicin in acute myeloid leukemia: two sides of the same coin","volume":"13","author":"Molica","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1280580","DOI":"10.3389\/fimmu.2023.1280580","article-title":"Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse\/refractory acute lymphoblastic leukemia: role of B-cell monitoring","volume":"14","author":"Molinos-Quintana","year":"2023","journal-title":"Front. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/V13071365","article-title":"Improved activity against acute myeloid leukemia with chimeric antigen receptor (CAR)-NK-92 cells designed to target CD123","volume":"13","author":"Morgan","year":"2021","journal-title":"Viruses"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1182\/BLOOD-2022-170201","article-title":"Safety and anti-leukemic activity of cd123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0028","article-title":"NCC clinical guidelines in oncology: acute myeloid leukemia","volume":"17","author":"Network","year":"2019","journal-title":"Natl. Compr. Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"eabq3010","DOI":"10.1126\/SCITRANSLMED.ABQ3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3390\/cancers14174318","article-title":"Current progress of CAR-NK therapy in cancer treatment","volume":"14","author":"Pang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B77","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.1002\/CAM4.5916","article-title":"Anti\u2010CLL1\u2010based CAR T\u2010cells with 4\u20101\u2010BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia","volume":"12","author":"Pei","year":"2023","journal-title":"Cancer Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/ijms24032718","article-title":"CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm","volume":"24","author":"Pelosi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.1182\/BLOOD-2022-165339","article-title":"CD84: a novel target for CAR T-cell therapy for acute myeloid leukemia","volume":"140","author":"P\u00e9rez-Amill","year":"2022","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/J.CCELL.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/BLOODADVANCES.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv."},{"key":"B82","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/SCITRANSLMED.AAJ2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/MT.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol. Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1182\/BLOOD-2022-169928","article-title":"Ameli-01: a phase I trial of UCART123v1.2, an anti-cd123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123+ acute myeloid leukemia (AML)","volume":"140","author":"Sallman","year":"","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"10313","DOI":"10.1182\/BLOOD-2022-169142","article-title":"Phase 1\/1b safety study of prgn-3006 ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes","volume":"140","author":"Sallman","year":"","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.7150\/JCA.28952","article-title":"Preclinical targeting of human acute myeloid leukemia using CD4-specific chimeric antigen receptor (CAR) T cells and NK cells","volume":"10","author":"Salman","year":"2019","journal-title":"J. Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1182\/BLOOD-2022-170503","article-title":"LigandCD70.CAR as a platform for dual-targeting CAR T cells for acute myeloid leukemia","volume":"140","author":"Scherer","year":"2022","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1085978","DOI":"10.3389\/FIMMU.2022.1085978","article-title":"Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia","volume":"13","author":"Schorr","year":"2022","journal-title":"Front. Immunol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"4600","DOI":"10.1182\/BLOOD-2022-168891","article-title":"Allogeneic donor-derived myeloid antigen directed CAR-T cells - for relapsed\/refractory acute myeloid leukemia in children after allogeneic hematopoietic stem cell transplantation: report of three cases","volume":"140","author":"Shelikhova","year":"2022","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"847008","DOI":"10.3389\/FIMMU.2022.847008","article-title":"Genetic engineering and enrichment of human NK cells for CAR-enhanced immunotherapy of hematological malignancies","volume":"13","author":"Soldierer","year":"2022","journal-title":"Front. Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/S41467-022-29668-9","article-title":"Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia","volume":"13","author":"Sugita","year":"2022","journal-title":"Nat. Commun."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/S41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"B96","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/BLOOD-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark. Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1034707","DOI":"10.3389\/FIMMU.2022.1034707","article-title":"Next generations of CAR-T cells - new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front. Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e004222","DOI":"10.1136\/JITC-2021-004222","article-title":"Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia","volume":"10","author":"Trad","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B100","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/MT.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"B101","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B102","doi-asserted-by":"publisher","first-page":"eadi1145","DOI":"10.1126\/SCITRANSLMED.ADI1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1182\/BLOOD.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/CJI.0b013e31819b7c8e","article-title":"The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum","volume":"32","author":"Westwood","year":"2009","journal-title":"J. Immunother."},{"key":"B105","doi-asserted-by":"publisher","first-page":"111299","DOI":"10.1016\/j.biopha.2021.111299","article-title":"Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia","volume":"137","author":"Wu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1097\/01.HS9.0000848572.60330.2F","article-title":"P1429: multiplex deletion of myeloid antigens CD33 and CLL-1 BY CRISPR\/CAS9 in human hematopoietic stem cells highlights the potential of next-generation transplants for aml treatment","volume":"6","author":"Xavier-Ferrucio","year":"2022","journal-title":"Hemasphere"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/FONC.2019.01358","article-title":"Donor-derived cd123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML","volume":"9","author":"Yao","year":"2019","journal-title":"Front. Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1038\/CTI.2016.73","article-title":"All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia","volume":"5","author":"Yoshida","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/CANCERS15112944","article-title":"CAR-T cells immunotherapies for the treatment of acute myeloid leukemia\u2014recent advances","volume":"15","author":"Zarychta","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B110","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1182\/blood-2023-179086","article-title":"Naturally selected CD7-targeted chimeric antigen receptor (CAR)-T cell therapy for refractory\/relapsed acute myeloid leukemia: phase I clinical trial","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1034257","DOI":"10.3389\/FCELL.2022.1034257","article-title":"Mechanisms of CAR T cell exhaustion and current counteraction strategies","volume":"10","author":"Zhu","year":"2022","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1376554\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T04:53:03Z","timestamp":1713329583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1376554\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":111,"alternative-id":["10.3389\/fcell.2024.1376554"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2024.1376554","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]},"article-number":"1376554"}}